艾瑞咨询：2021年中国医疗器械国产替代趋势研究报告-39页_2mb.pdf
2022.01 iResearch Inc.2 iResearch I 70 80 2020 34998 4.6%8118 15.5%3 DRGs/DIP 2018 2020 IVD 1 234 54 iResearch I 2020 1949-1978 2013-1978-201320201952 1980 20101963 1984 200 X A 6 10005 iResearch I/NMPA;6 iResearch I,%IVD%7 iResearch I X IVD TLA POCT 8 iResearch I IVD9 iResearch I 34.5%22.5%11.3%11.1%8.7%7.6%4.4%2020 24.1%24.1%17.0%10.6%9.6%8.6%6.0%2020 30%20%10%20%36.4%24.8%12.5%9.0%8.1%5.8%3.4%2020,37.6%,24.3%,15.3%,7.4%,5.9%,5.5%,4.1%202010 iResearch I 2021 2020 34998 4.6%2025 418852014-2020 4.5%2020 8118 15.5%4 2021 28065 29360 31095 31926 33196 33467 34998 37074 38067 39584 39888 41885 18892064214921496274 7028 8118 9641 11736 13175 14859 17168 4.6%5.9%2.7%4.0%0.8%4.6%5.9%2.7%4.0%0.8%5.0%28.9%21.9%12.4%21.3%12.0%15.5%18.8%21.7%12.3%12.8%15.5%2014 2015 2016 2017 2018 2019 2020 2021e 2022e 2023e 2024e 2025e2014-2025&2022.1 iResearch I 2022.1 iResearch I 2020 2.65 1.55 1.30 2181 2020 CAGR 15-20+25.1%+6.5%-3.5%2015-2020 2015-2020 5080 497960967513823215536951789579340918910033130112614236621891997197721822015 2016 2017 2018 2019 2020(4006008001000 1112 iResearch I 2 90%2000 20 14.2%70%-80%13 iResearch I384 608 890 1141 1405 1747 2257 3040 3672 4309 5539 6939 8248 9687 11193 13084 17931 21384 24421 244 409 654 862 1079 1277 1562 2084 2797 3538 4431 5544 6801 8134 9312 10767 14422 17823 20854 0%10%20%30%40%50%60%70%2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 20192001-2019()()YOY%YOY%1993-2008 2016-2022 1999 05 12 2000 05 25 2016 20172020 4 2019 15%3 2020 3 2009 2012 2009-201514 iResearch I CT 10 10 100 1000 10000 6 1000 2025 2025 2025 2030 2030/23 DR MRI CT PET-CT PET/MR DSA 2018 2020 1 23 416 iResearch I22134 6019 2516 2225 1736 1360 1267 6721928 440 316 281 241 208 186 123 96 37 74%2021 73953 1999.5 17 39867 22134 74%17 iResearch I56.3%54.2%50.0%44.0%26.9%20.5%82.0%67.3%67.3%53.4%47.2%35.3%32.1%53.0%51.0%96.0%85.3%74.4%46.8%15.9%79.6%75.9%68.9%49.0%73.1%+N VBP VBP VBP VBP 96.0%2021 12 27 2022(%)2022.1 iResearch I 2022.1 iResearch I92986766810671010593189235315244-6.7%-23.0%59.7%-5.3%-68.1%24.3%34.0%-22.5%2016 2017 2018 2019 2020 3)3 3 YOY(%)3 YOY%609359934402613513636440 389 358 344 308-1.6%-26.5%39.4%122.3%-11.6%-8.0%-3.9%-10.5%2016 2017 2018 2019 2020 2 2 2 YOY%2 YOY%2020 2 2016-2020&3 2016-2020&2 1819 iResearch I VBP VBP VBP VBP VBP DRG VBP DRG VBP VBP 20 iResearch I/“”“”1 23 42022.1 iResearch I 2022.1 iResearch I25412228582225926543290113221831659967071009929989894144888478139376306190591447611934100688821751063682020 2015 2010 2005 2000 1995 1990 1990-2020 0-14()15-64()65()9.79.14.54.715.921.719.518.823.228.0 11.0 26.0 32.7 29.1 36.6 43.0 32.9 31.5 83.2 68.6 49.7 49.0 43.5 38.0 34.1 31.4 2019 0-14 15-44 45-59 60 2020 2019 60 83.2%60 2.64 2020 2020(%)(%)(%)(%)2223 iResearch I IT IT IBM 24 iResearch I DRGs/DIP(2021 137 100%12 75%24 50%5 25%25 iResearch I DSA CT MRI 26 iResearch I 50%2015-2020 IVD 90.0%75.0%55.0%25.0%20.0%5.7%3.0%75.0%68.0%39.0%30.0%30.0%27.0%20.0%20.0%5.0%40.0%30.0%30.0%30.0%30.0%95.0%95.0%DR CT DSA POCT IVD 27 iResearch I19.9%14.3%11.4%9.7%9.0%8.7%8.2%7.4%4.9%4.8%4.4%2.6%14.8%11.3%9.7%8.0%6.2%02018-2020 2018-2020 3 10%10%8.8%20%8.8%10%28 iResearch I license-in-Optune license-in license-in-Bemarituzumab-Retifanlimab-BA-3071 License-in 1 23 430 iResearch I license-in 31 iResearch I“AI+”AI+”AI 5G AI CDSS AI VTE 32 iResearch I license-in 2022.1 iResearch I 2022.1 iResearch I24423723220520319913813712912912811510310291898584823319 107 83 77 50 40 33 21 16 14 10 8 7 6 5 4 4 3 3 2 1 1 2021 H1 2020 50%2021 50%3334 iResearch I 2018 2020 IVD 286 228 115 83 80 43 33 27 22 17 15 15 14 12 11 8 4 4 3 1621341244852252019390381193133IVD 2018&2020 2020 2018 86 39 30 28 11 8 6 5 IVD AI 2021 35 iResearch I 50%1.2.DR 3.4.2012 2025 64.80%DSA DSA 10 IPO 2002 3000 400-026-Contact Us
